Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
Posted:
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient survival — the gold standard outcome of any cancer study.
New York-based Claryx has emerged from stealth with $3.5 million in pre-seed funding.
Outlander VC led the round, with participation from Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford and Precursor Ventures.
The funding will help Claryx continue to "build…
Researchers have shown that measurements taken from a person's fingertip could help identify physical patterns associated with stress, anxiety and depression.
The international study, involving experts from Aston University, used a wearable device that shines light into the skin to…
Attendees
Sponsors and Exhibitors
Contact us